

Exhibit 1
MINDRAY MEDICAL INTERNATIONAL LIMITED
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands of US dollars)

	As of December 31, 2014 US\$ (Note 1)	As of March 31, 2015 US\$ (unaudited)
ASSETS		
Current assets:		
Cash and cash equivalents (Note 2)	276,598	221,699
Restricted cash (Note 3)	7,422	10,681
Restricted Investments (Note 4)	-	242,991
Short-term investments (Note 2)	816,394	640,019
Accounts receivable, net	222,522	180,571
Inventories	150,642	164,382
Value added tax receivables	3,432	10,500
Other receivables and current assets	23,316	24,216
Prepayments and deposits	16,481	16,585
Deferred tax assets, net	14,802	16,208
Total current assets	1,531,609	1,527,852
Restricted cash, non-current (Note 3)	5,061	2,771
Other assets	9,666	9,420
Accounts receivables, net, non-current	3,350	3,423
Advances for purchase of property, plant and equipment	21,840	24,548
Property, plant and equipment, net	412,733	416,240
Land use rights, net	59,057	58,488
Intangible assets, net	175,451	169,994
Goodwill	254,435	254,115
Total assets	2,473,202	2,466,851
LIABILITIES AND EQUITY		
Current liabilities:		
Short-term bank loans	59,625	111,638
Notes payable	9,234	9,615
Accounts payable	93,523	83,006
Advances from customers	31,396	56,330
Salaries payable	114,583	64,439
Other payables and current liabilities	168,139	168,827
Purchase consideration payable	17,173	14,647
Income taxes payable	20,415	25,762
Other taxes payable	10,342	5,746
Total current liabilities	524,430	540,010
Long-term bank loans	197,585	189,000
Other long-term liabilities	10,670	10,856
Deferred tax liabilities, net	69,233	71,933
Total liabilities	801,918	811,799
Mindray shareholders' equity:		
Ordinary shares	15	15
Additional paid-in capital	453,564	458,782
Retained earnings	1,000,257	985,334
Accumulated other comprehensive income	144,120	135,953
Total Mindray shareholders' equity	1,597,956	1,580,084
Non-controlling interests	73,328	74,968
Total equity	1,671,284	1,655,052
Total liabilities and equity	2,473,202	2,466,851

- (1) Financial information is extracted from the audited financial statements included in the Company's 2014 annual report on Form 20-F.
- (2) In respect of cash and cash equivalents and short-term investments, there is an aggregate compensating balance arrangement of \$189,000 and \$nil as of December 31, 2014 and March 31, 2015, respectively in relation to the drawings of certain bank loans.
- (3) Restricted cash are mainly those purchase consideration in connection with our acquisitions being held on escrow accounts.
- (4) Restricted investments are those investments in Chinese Renminbi denominated financial products placed with bank which are restricted as to withdrawal or usage according to new terms imposed on certain bank loans during the quarter ended March 31, 2015.

Exhibit 2
MINDRAY MEDICAL INTERNATIONAL LIMITED
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands of US dollars, except share and per share amounts)

	Three months ended March 31,	
	2014	2015
	US\$	US\$
	(unaudited)	(unaudited)
Net revenues		
- <i>China</i>	115,828	121,957
- <i>International</i>	148,943	150,507
Net revenues	264,771	272,464
Cost of revenues	(118,751)	(123,629)
Gross profit	146,020	148,835
Selling expenses	(54,796)	(56,458)
General and administrative expenses	(29,813)	(26,953)
Research and development expenses	(30,143)	(34,486)
Income from operations	31,268	30,938
Other income, net	1,809	885
Interest income	10,779	11,282
Interest expense	(2,395)	(985)
Income before income taxes and non-controlling interests	41,461	42,120
Income tax provision	(4,500)	(8,306)
Net income	36,961	33,814
Less: Net income attributable to non-controlling interests	(1,323)	(1,640)
Net income attributable to Mindray shareholders	35,638	32,174
Basic earnings per share	0.30	0.27
Diluted earnings per share	0.30	0.27
Shares used in the computation of:		
Basic earnings per share	116,854,637	117,814,582
Diluted earnings per share	118,270,656	118,701,761

Exhibit 3
MINDRAY MEDICAL INTERNATIONAL LIMITED
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands of US dollars)

	Three months ended March 31,	
	2014	2015
	US\$	US\$
	(unaudited)	(unaudited)
Cash flow from operating activities:		
Net income	36,961	33,814
Adjustments to reconcile net income to net cash provided by operating activities	27,864	23,858
Changes in assets and liabilities, net of effects of acquisition	(45,159)	(20,680)
Net cash provided by operating activities	19,666	36,992
Cash flow from investing activities:		
Acquisition cost of subsidiaries, net of cash received	(2,206)	(2,507)
Capital expenditures	(27,875)	(30,780)
Decrease in restricted cash and restricted investment	(6,455)	(53,114)
Proceeds from sale of short-term investments	241,964	9,777
Increase in short-term investments and changes in other investing activities	(12,965)	(16,383)
Net cash provided by (used in) investing activities	192,463	(93,007)
Cash flow from financing activities:		
Repayment of bank loans	(50,000)	-
Proceeds from bank loans, net of costs	-	47,712
Dividend paid	(58,711)	(47,097)
Proceeds from exercise of options	345	1,615
Repurchase of ordinary American depositary shares	(68,029)	-
Cash paid to acquire a non-controlling interest	(445)	-
Cash contribution from a non-controlling interest	239	-
Net cash (used in) provided by financing activities	(176,601)	2,230
Net increase (decrease) in cash and cash equivalents	35,528	(53,785)
Cash and cash equivalents, beginning of period	385,224	276,598
Effect of exchange rate changes on cash and cash equivalents	(932)	(1,114)
Cash and cash equivalents, end of period	419,820	221,699

MINDRAY MEDICAL INTERNATIONAL LIMITED
RECONCILIATIONS OF NON-GAAP RESULTS OF OPERATIONS MEASURES TO THE NEAREST COMPARABLE GAAP MEASURES

(In thousands of US dollars, except share and per share amounts)

	Three months ended March 31,	
	2014	2015
	(unaudited)	(unaudited)
	US\$	US\$
Non-GAAP net income attributable to the Company	46,054	39,458
<i>Non-GAAP net margin</i>	17.4%	14.5%
Amortization of acquired intangible assets	(3,447)	(3,378)
Deferred tax impact related to acquired intangible assets	615	618
Dispute related legal fees, net of related tax impact	-	(920)
Share-based compensation	(7,584)	(3,604)
GAAP net income attributable to the Company	35,638	32,174
<i>GAAP net margin</i>	13.5%	11.8%
 Non-GAAP basic earnings per share	0.39	0.33
Non-GAAP diluted earnings per share	0.39	0.33
 GAAP basic earnings per share	0.30	0.27
GAAP diluted earnings per share	0.30	0.27
 Shares used in computation of:		
Basic earnings per share	116,854,637	117,814,582
Diluted earnings per share	118,270,656	118,701,761
 Non-GAAP operating income	42,299	39,002
<i>Non-GAAP operating margin</i>	16.0%	14.3%
Amortization of acquired intangible assets	(3,447)	(3,378)
Dispute related legal fees	-	(1,082)
Share-based compensation	(7,584)	(3,604)
GAAP operating income	31,268	30,938
<i>GAAP operating margin</i>	11.8%	11.4%
 Non-GAAP gross profit	148,124	150,919
<i>Non-GAAP gross margin</i>	55.9%	55.4%
Amortization of acquired intangible assets	(1,931)	(1,790)
Share-based compensation	(173)	(294)
GAAP gross profit	146,020	148,835
<i>GAAP gross margin</i>	55.1%	54.6%
 Non-GAAP selling expenses	(52,174)	(53,559)
<i>Non-GAAP as % of total net revenues</i>	19.7%	19.7%
Amortization of acquired intangible assets	(1,516)	(1,588)
Share-based compensation	(1,106)	(1,311)
GAAP selling expenses	(54,796)	(56,458)
<i>GAAP as % of total net revenues</i>	20.7%	20.7%
 Non-GAAP general and administrative expenses	(24,562)	(25,097)
<i>Non-GAAP as % of total net revenues</i>	9.3%	9.2%
Dispute related legal fees	-	(1,082)
Share-based compensation	(5,251)	(774)
GAAP general and administrative expenses	(29,813)	(26,953)
<i>GAAP as % of total net revenues</i>	11.3%	9.9%
 Non-GAAP research and development expenses	(29,089)	(33,261)
<i>Non-GAAP as % of total net revenues</i>	11.0%	12.2%
Share-based compensation	(1,054)	(1,225)
GAAP research and development expenses	(30,143)	(34,486)
<i>GAAP as % of total net revenues</i>	11.4%	12.7%

MINDRAY MEDICAL INTERNATIONAL LIMITED**RECONCILIATIONS OF NON-GAAP RESULTS OF OPERATIONS MEASURES TO THE NEAREST COMPARABLE GAAP MEASURES****(In thousands of US dollars, except share and per share amounts)**

	Three months ended March 31,	
	2014	2015
	US\$ (unaudited)	US\$ (unaudited)
GAAP net income attributable to the Company	35,638	32,174
Interest income	(10,779)	(11,282)
Interest expense	2,395	985
Income tax provision	4,500	8,306
Earnings before interest and taxes ("EBIT")	31,754	30,183
Depreciation	8,628	9,822
Amortization	5,579	5,518
Earnings before interest, taxes, depreciation, and amortization ("EBITDA")	45,961	45,523